The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality - Cancer Treatment Reviews
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer - Journal of Hepatology
MTS trials coming soon - BreastCancerTrials.org
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma - Cancer Treatment Reviews
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? | Clinical Cancer Research
Systemic therapies for intrahepatic cholangiocarcinoma - Journal of Hepatology
Petros Grivas on Twitter: "@IyerGopa presented on FGFRi in urothelial Ca including fda-approved erdafitinib & other agents, e.g. infigratinib adjuvant trial & Fuze trial for FGFR fusions! Debate ongoing on FGFR alterations
Find a clinical trial that is right for you
Clinical Trials | Research Study | MedStar Health
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma | HTML
Practical considerations in screening for genetic alterations in cholangiocarcinoma - Annals of Oncology
Study history - Phase1
Full article: Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials
Active Trials - Head and Neck Cancer Alliance
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
IJMS | Free Full-Text | Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives | HTML
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers | Clinical Cancer Research
Beyond Cancer Type: New Pan-Tumor Targets Emerge
2019 ASCO Annual Meeting Proceedings Immuno-Oncology Abstracts | Journal of Clinical Oncology
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1 FGFR2 or FGFR3- (FUZE Clinical Trial) | Clinical Research Trial Listing ( Solid Tumor ) ( NCT03834220 )
